The Senate Finance Committee today held a hearing on strategies to reduce prescription drug costs and encourage innovation and competition in the market. Health and Human Services Secretary Alex Azar testified on the administration’s blueprint to lower drug prices, released in May. In a statement submitted to the committee, AHA urged Congress to pass the Creating and Restoring Equal Access to Equivalent Samples Act to prevent anticompetitive behaviors used to block and delay entry of generic drugs; and H.R. 4392 to prevent a 30% reduction in Medicare payment to certain hospitals for outpatient drugs purchased under the 340B drug savings program, among other actions. Hospital spending on inpatient drugs increased 38.7% per admission between 2013 and 2015, more than three times the increase in spending for retail prescription drugs over the period, the statement notes.

Related News Articles

Headline
Cigna’s Evernorth division Oct. 27 announced a new, rebate-free pharmacy benefit model, beginning in 2027, that would reduce monthly prescription drug costs by…
Headline
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
The Department of Health and Human Services today announced prescription drug reforms that will become effective Oct. 1 originating from the Health Data,…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…